| 2026-08-03 21:54 |
8-K |
["1.01", "2.01"] |
merger agreement |
1.00
|
Galera Therapeutics completed merger with Obsidian Therapeutics on August 3, 2026, per definitive merger agreement dated April 14, 2026. |
SEC · detail |
| 2026-07-31 16:31 |
8-K |
["3.02", "7.01", "9.01"] |
merger agreement |
0.98
|
Galera completing merger with Obsidian into Gazelle Parent; closing expected Aug 3, 2026 with $350M PIPE financing. |
SEC · detail |
| 2026-07-13 16:01 |
8-K |
["3.03", "5.03", "9.01"] |
other |
0.15
|
Reverse stock split (1:200) filed; typical distressed equity restructuring with no M&A signals. |
SEC · detail |
| 2026-07-07 08:49 |
8-K |
["8.01"] |
other |
0.05
|
Reverse stock split announcement; no M&A signal present. |
SEC · detail |
| 2026-05-19 16:01 |
8-K |
["8.01"] |
other |
0.05
|
Routine conversion of Series B preferred stock to common stock; no M&A signal. |
SEC · detail |
| 2026-05-15 06:30 |
8-K |
["5.03", "9.01"] |
other |
0.62
|
Charter amendments increasing authorized shares and adding written consent rights are defensive/flexibility measures consistent with M&A preparation. |
SEC · detail |
| 2026-05-11 16:02 |
8-K |
["5.07"] |
other |
0.25
|
Routine annual stockholder meeting with charter amendments; reverse stock split approved but no M&A indicators present. |
SEC · detail |